Source comparison
MOTS-c vs SS-31: Which Peptide Works Better?
Research published in Cell Metabolism showed that MOTS-c administration improved glucose metabolism and increased insulin sensitivity in diet-induced obese mice. But here's what most summaries miss: the effect was mediated entirely through AMPK activation in s
This comparison does not assign a generated winner or score.
- Research published in Cell Metabolism showed that MOTS-c administration improved glucose metabolism and increased insulin sensitivity in diet-induced obese mice. But here's what most summaries miss: the effect was mediated entirely through AMPK activation in skeletal muscle, not through mitochondrial biogenesis. SS-31 (also called elamipretide), by contrast, binds directly to cardiolipin in the inner mitochondrial membrane to preserve cristae structure under oxidative stress, with no direct metabolic signaling effect. They're not competing treatments. They target completely separate mitochondrial pathways.
- Our team has worked extensively with researchers evaluating mitochondrial-targeting peptides for metabolic and cardioprotective applications. The most common mistake we see in peptide comparisons is treating all mitochondrial peptides as interchangeable when their mechanisms couldn't be more distinct.
- What's the difference between MOTS-c and SS-31?
- MOTS-c is a mitochondrial-derived peptide (MDP) encoded in the mitochondrial 12S rRNA gene that acts as a metabolic regulator by activating AMPK signaling pathways. Improving insulin sensitivity, glucose uptake, and fatty acid oxidation. SS-31 is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) that selectively binds cardiolipin on the inner mitochondrial membrane to stabilize cristae structure, reduce ROS production, and preserve ATP synthesis under oxidative stress. MOTS-c addresses metabolic dysfunction; SS-31 protects against acute mitochondrial damage.